David Weisman
Advanced in Dementia

Dr. David Weisman

Neurology
Jefferson Health
1151 Old York Road, Suite 200, 
Abington, PA 
Accepting New Patients
Offers Telehealth
Advanced in Dementia
Jefferson Health
1151 Old York Road, Suite 200, 
Abington, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Weisman is a Neurologist in Abington, Pennsylvania. Dr. Weisman is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Lewy Body Dementia (LBD), Cerebellar Degeneration, and Dementia. Dr. Weisman is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 16 clinical trials in the study of Dementia.

Graduate Institution
Pennsylvania State School Of Medicine - Hershey
Residency
Yale-New Haven Hospital
Specialties
Neurology
Licenses
Behavioral Neurology & Neuropsychiatry in PA
Board Certifications
Neurology
Fellowships
UC San Diego Medical Center
Hospital Affiliations
Jefferson Abington Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

1151 Old York Road, Suite 200, Abington, PA 19001

Additional Areas of Focus

Dr. Weisman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Alzheimer's Disease
Bell's Palsy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 07, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drug: AL002
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US
International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US
Enrollment Status: Terminated
Publish Date: April 18, 2023
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)
Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)
Enrollment Status: Completed
Publish Date: April 30, 2020
Intervention Type: Other
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Enrollment Status: Completed
Publish Date: December 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 16 Less Clinical Trials

3 Total Publications

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 22, 2024
View All 3 Publications
Similar Doctors
Elite in Dementia
Dr. David A. Wolk
Neurology
Elite in Dementia
Dr. David A. Wolk
Neurology

Perelman Center For Advanced Medicine

3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
 (14.2 miles away)
215-662-7810
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Wolk is a Neurologist in Philadelphia, Pennsylvania. Dr. Wolk is rated as an Elite provider by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Alzheimer's Disease, Frontotemporal Dementia, Lewy Body Dementia (LBD), and Deep Brain Stimulation. Dr. Wolk is currently accepting new patients.

Distinguished in Dementia
Dr. Alice S. Chen
Neurology
Distinguished in Dementia
Dr. Alice S. Chen
Neurology

Penn Neurology Pennsylvania Hospital

330 South 9th Street, 3rd Floor, 
Philadelphia, PA 
 (13.9 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances

Alice Chen is a Neurologist in Philadelphia, Pennsylvania. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Dementia. Her top areas of expertise are Parkinson's Disease, Movement Disorders, Lewy Body Dementia (LBD), and Dementia.

Distinguished in Dementia
Dr. Andrew D. Siderowf
Neurology
Distinguished in Dementia
Dr. Andrew D. Siderowf
Neurology

Penn Neurology Pennsylvania Hospital

330 South 9th Street, 3rd Floor, 
Philadelphia, PA 
 (13.9 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Siderowf is a Neurologist in Philadelphia, Pennsylvania. Dr. Siderowf is rated as an Elite provider by MediFind in the treatment of Dementia. His top areas of expertise are Parkinson's Disease, Movement Disorders, Lewy Body Dementia (LBD), and Dementia. Dr. Siderowf is currently accepting new patients.

VIEW MORE DEMENTIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weisman's expertise for a condition
ConditionClose
    • Distinguished
    • Alzheimer's Disease
      Dr. Weisman is
      Distinguished
      . Learn about Alzheimer's Disease.
      See more Alzheimer's Disease experts
    • Advanced
    • Cerebellar Degeneration
      Dr. Weisman is
      Advanced
      . Learn about Cerebellar Degeneration.
      See more Cerebellar Degeneration experts
    • Dementia
      Dr. Weisman is
      Advanced
      . Learn about Dementia.
      See more Dementia experts
    • Lewy Body Dementia (LBD)
      Dr. Weisman is
      Advanced
      . Learn about Lewy Body Dementia (LBD).
      See more Lewy Body Dementia (LBD) experts
    • Experienced
    • Chronic Inflammatory Demyelinating Polyneuropathy
      Dr. Weisman is
      Experienced
      . Learn about Chronic Inflammatory Demyelinating Polyneuropathy.
      See more Chronic Inflammatory Demyelinating Polyneuropathy experts
    • Chronic Polyradiculoneuritis
      Dr. Weisman is
      Experienced
      . Learn about Chronic Polyradiculoneuritis.
      See more Chronic Polyradiculoneuritis experts
    • Developmental Dysphasia Familial
      Dr. Weisman is
      Experienced
      . Learn about Developmental Dysphasia Familial.
      See more Developmental Dysphasia Familial experts
    • Developmental Expressive Language Disorder
      Dr. Weisman is
      Experienced
      . Learn about Developmental Expressive Language Disorder.
      See more Developmental Expressive Language Disorder experts
    • Generalized Tonic-Clonic Seizure
      Dr. Weisman is
      Experienced
      . Learn about Generalized Tonic-Clonic Seizure.
      See more Generalized Tonic-Clonic Seizure experts
    • Guillain-Barre Syndrome
      Dr. Weisman is
      Experienced
      . Learn about Guillain-Barre Syndrome.
      See more Guillain-Barre Syndrome experts
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.